Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ATHE

Alterity Therapeutics Ltd ADR

Nov 28 • 03:05PM ET

1.77

Dollar change +0.04
Percentage change 2.31	%

Healthcare • Biotechnology • Australia • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.30	Insider Own	4.67%	Shs Outstand	4.07M	Perf Week	-24.69%
Market Cap	7.20M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.88M	Perf Month	-26.86%
Income	-9.28M	PEG	-	EPS next Q	-	Inst Own	1.43%	Short Float / Ratio	0.17% / 1.05	Perf Quarter	-34.93%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-45.45%	Short Interest	0.01M	Perf Half Y	-39.18%
Book/sh	3.73	P/B	0.47	EPS next Y	-	ROA	-39.81%	Target Price	10.00	Perf Year	-51.54%
Cash/sh	2.58	P/C	0.69	EPS next 5Y	-	ROE	-46.90%	52W Range	1.55 - 4.45	Perf YTD	-49.17%
Dividend	-	P/FCF	-	EPS past 5Y	20.43%	ROI	-60.84%	52W High	-60.23%	Beta	1.04
Dividend %	-	Quick Ratio	6.17	Sales past 5Y	0.00%	Gross Margin	-	52W Low	14.19%	ATR	0.22
Employees	11	Current Ratio	6.17	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	37.91	Volatility	9.68% 6.65%
Optionable	No	Debt/Eq	0.01	EPS Q/Q	14.33%	Profit Margin	-	Rel Volume	1.07	Prev Close	1.73
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 31 AMC	Payout	-	Avg Volume	6.14K	Price	1.77
Recom	1.00	SMA20	-24.01%	SMA50	-28.53%	SMA200	-37.47%	Volume	5,948	Change	2.31%

Nov-27-23 07:25AM	Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy (GlobeNewswire) -6.49%
Nov-16-23 07:25AM	Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434 (GlobeNewswire)
Nov-08-23 07:25AM	Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +12.77%
Oct-30-23 07:25AM	Appendix 4C Q1 FY24 Quarterly Cash Flow Report (GlobeNewswire) -5.98%
Aug-31-23 07:25AM	Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder (GlobeNewswire)
07:25AM	Loading…
Aug-23-23 07:25AM	Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinsons and Alzheimers (GlobeNewswire)
Aug-22-23 07:25AM	Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinsons Disease and Movement Disorders (GlobeNewswire)
Aug-15-23 07:25AM	Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund (GlobeNewswire)
Jul-31-23 07:52AM	Appendix 4C Q4 FY23 Quarterly Cash Flow Report (GlobeNewswire)
Jul-26-23 07:25AM	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned (GlobeNewswire) +6.49%
Jun-21-23 07:25AM	Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023 (GlobeNewswire)
May-30-23 07:25AM	Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder (GlobeNewswire) +6.51%
May-19-23 07:25AM	Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023 (GlobeNewswire)
May-10-23 07:25AM	Appendix 4C Q3 FY23 Quarterly Cash Flow Report (GlobeNewswire)
07:25AM	Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
07:25AM	Loading…
Apr-26-23 07:25AM	Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology (GlobeNewswire)
Apr-04-23 07:25AM	Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
Mar-16-23 07:25AM	Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire) +6.70%
Mar-14-23 07:25AM	Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimers Disease (GlobeNewswire) -7.14%
Mar-08-23 07:25AM	Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (GlobeNewswire)
Feb-16-23 04:44PM	Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial (GlobeNewswire) +7.64%
Jan-31-23 07:25AM	Appendix 4C - Q2 FY23 Quarterly Cash Flow Report (PR Newswire) -5.78%
Jan-30-23 07:25AM	Alteritys ATH434 Prevents Loss of Brain Cells in Parkinsons Disease Animal Model (GlobeNewswire) +6.14%
Jan-25-23 07:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy (GlobeNewswire)
Jan-20-23 09:40AM	Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-09-23 10:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy (PR Newswire)
Jan-06-23 07:25AM	Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) (PR Newswire)
Jan-03-23 10:25AM	Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (PR Newswire)
Dec-29-22 10:25AM	Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office (PR Newswire) +16.91%
Nov-07-22 10:25AM	Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting (PR Newswire)
07:25AM	Loading…
Oct-28-22 07:25AM	Appendix 4C - Q1 FY23 Quarterly Cash Flow Report (PR Newswire)
Oct-26-22 07:25AM	Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting (PR Newswire)
Oct-13-22 10:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy (PR Newswire)
Sep-26-22 07:25AM	Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
Sep-20-22 07:25AM	Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy (PR Newswire) -10.71%
Aug-25-22 07:25AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe (PR Newswire)
Aug-08-22 04:00PM	Is Alterity Therapeutics (ASX:ATH) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jul-22-22 07:25AM	Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report (PR Newswire)
Jul-06-22 11:00AM	Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy (PR Newswire)
Jun-24-22 08:35AM	Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Jun-23-22 11:00AM	Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy (PR Newswire) +5.24%
Jun-21-22 04:21PM	UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd (GlobeNewswire)
08:35AM	Life Sciences Investor Forum: Company Executives Present Live June 23rd (GlobeNewswire)
Jun-20-22 07:05AM	Alterity Therapeutics to Present at the VirtualInvestorConferences.com Life Sciences Investor Forum (GlobeNewswire)
Jun-02-22 08:00AM	Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy (PR Newswire)
May-31-22 08:27AM	Safe-T Group Reports Record First Quarter 2022 Results with Revenues of $4.02 Million, Up 199% Over First Quarter 2021 Results (GlobeNewswire)
Apr-27-22 07:40AM	Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom (PR Newswire)
Apr-06-22 09:34PM	Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting (PR Newswire)
Jan-28-22 11:02AM	Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease (Benzinga) +8.95%
07:08AM	Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease (PR Newswire)
Jan-27-22 07:45AM	Appendix 4C - Q2 FY22 Quarterly Cash Flow Report (PR Newswire)
Jan-06-22 07:30AM	Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's (PR Newswire) +33.85%
Jan-05-22 07:45AM	Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (PR Newswire)
Dec-14-21 07:25AM	Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial (PR Newswire)
Nov-22-21 07:50AM	Alterity Therapeutics to Participate in Two Upcoming Investor Conferences (PR Newswire) -5.56%
Nov-09-21 07:30AM	Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021 (PR Newswire)
Nov-05-21 02:57AM	Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases (PR Newswire)
Nov-04-21 07:30AM	Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases (PR Newswire)
Oct-29-21 02:50AM	Appendix 4C - Q1 FY22 Quarterly Cash Flow Report (PR Newswire)
Oct-19-21 05:08PM	Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program (PR Newswire)
Sep-20-21 10:51AM	Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 (PR Newswire)
Aug-04-21 08:39AM	Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's (PR Newswire) +14.29%
Jul-30-21 09:05AM	Appendix 4C - Q4 FY21 Quarterly Cash Flow Report (PR Newswire)
Jul-15-21 09:52AM	Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function (PR Newswire) +7.91%
Jul-01-21 11:51AM	Want to Buy Alterity Therapeutics (ATHE) Stock? See This First. (Benzinga) +64.62%
07:50AM	Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's (PR Newswire)
Jun-23-21 09:21AM	Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial (PR Newswire)
Jun-07-21 11:04AM	Alterity Therapeutics (ASX:ATH) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) +10.29%
Apr-29-21 08:30AM	Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report (PR Newswire)
Apr-21-21 09:25AM	Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder (Benzinga) +15.20%
08:11AM	ATH434 protects brain cells and improves motor function in Parkinsonian disorder (PR Newswire)
Feb-26-21 07:45AM	Alterity to present at the 7th International Congress of Multiple System Atrophy (PR Newswire) -5.33%
Feb-09-21 08:53AM	Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials (PR Newswire) +10.10%
Jan-07-21 08:00AM	Dr David Stamler Appointed CEO (PR Newswire)
Dec-21-20 08:30AM	Alterity and UniQuest partner to reverse bacterial resistance to antibiotics (PR Newswire)
Dec-09-20 09:46AM	Is Alterity Therapeutics (ASX:ATH) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-16-20 10:42AM	Alterity Therapeutics stock more than doubles on massive volume after new patent announcement (MarketWatch) +146.09%
08:42AM	Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases (PR Newswire)
Oct-26-20 10:03PM	Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study (PR Newswire)
Aug-05-20 03:10PM	Why Alterity's Stock Is Trading Lower Today (Benzinga) -15.16%
Aug-04-20 09:07AM	Alterity's stock nearly triples on heavy volume after update on study of treatment for MSA, Parkinson's (MarketWatch) +154.07%
02:33AM	Alterity Therapeutics Shares Surge As Company Says Animal Testing Data Positive For MSA Drug (Benzinga)
Aug-03-20 09:33PM	New data independently confirms and extends laboratory findings and expands safety profile of ATH434 (PR Newswire) -7.53%
Jul-30-20 06:49PM	Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report (PR Newswire)
Jul-01-20 08:12AM	The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes (Benzinga) +57.14%
Jun-29-20 11:14PM	Alterity Therapeutics meeting with US FDA provides development pathway for ATH434 (PR Newswire)
May-20-20 08:58PM	Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology (PR Newswire)
Apr-30-20 04:35AM	Alterity Therapeutics Limited Releases Its Appendix 4C - Q3 FY20 Quarterly Cash Flow Report (PR Newswire)
Apr-21-20 05:50PM	How Should Investors React To Alterity Therapeutics Limited's (ASX:ATH) CEO Pay? (Simply Wall St.)
Feb-21-20 07:15PM	Imagine Owning Alterity Therapeutics (ASX:ATH) And Trying To Stomach The 86% Share Price Drop (Simply Wall St.) -5.21%
Nov-11-19 10:30PM	Companies Like Alterity Therapeutics (ASX:ATH) Can Be Considered Quite Risky (Simply Wall St.)
Sep-12-19 11:07PM	Does Alterity Therapeutics Limited's (ASX:ATH) CEO Salary Reflect Performance? (Simply Wall St.)
Jul-29-19 08:00AM	Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial (Business Wire)
Jul-11-19 09:31PM	Imagine Owning Alterity Therapeutics (ASX:ATH) And Trying To Stomach The 89% Share Price Drop (Simply Wall St.) -6.30%
May-06-19 08:00AM	Initial Data for Alterity Therapeutics Phase 1 Clinical Trial Released at American Academy of Neurology Annual Meeting (Business Wire) -5.38%
May-03-19 08:00AM	Alterity Therapeutics Presents at the American Academy of Neurology Annual Meeting (Business Wire) +14.81%

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson's, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATHE

Alterity Therapeutics Ltd ADR

Upgrade your FINVIZ experience